Key Points
- Xenon Pharmaceuticals CFO Thomas Patrick Kelly purchased 15,000 shares at an average price of $37.32, representing a total investment of $559,800.
- XENE shares opened at $38.93 and have traded between $36.07 and $72.66 over the past year; the company has a market capitalization of approximately $3.76 billion.
- Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $70.27, although several firms recently lowered their targets.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CFO Thomas Patrick Kelly purchased 15,000 shares of the company's stock in a transaction dated Wednesday, September 30th. The stock was acquired at an average price of $37.32 per share, with a total value of $559,800.00. Following the completion of the transaction, the chief financial officer owned 15,000 shares of the company's stock, valued at $559,800. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Xenon Pharmaceuticals Trading Up 4.7%
Shares of XENE stock opened at $38.93 on Friday. The stock has a 50 day simple moving average of $56.86 and a 200 day simple moving average of $57.16. The stock has a market cap of $3.76 billion, a P/E ratio of -8.21 and a beta of 0.60. Xenon Pharmaceuticals Inc. has a 1 year low of $36.07 and a 1 year high of $72.66.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same period last year, the business earned ($1.07) EPS. Analysts forecast that Xenon Pharmaceuticals Inc. will post -4.7 EPS for the current year.
Institutional Trading of Xenon Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Corient Private Wealth LP boosted its position in Xenon Pharmaceuticals by 1.5% during the second quarter. Corient Private Wealth LP now owns 28,732 shares of the biopharmaceutical company's stock worth $1,734,000 after purchasing an additional 430 shares during the period. Arizona State Retirement System grew its position in shares of Xenon Pharmaceuticals by 2.3% during the 2nd quarter. Arizona State Retirement System now owns 22,382 shares of the biopharmaceutical company's stock valued at $1,351,000 after purchasing an additional 513 shares in the last quarter. Royal Bank of Canada grew its position in Xenon Pharmaceuticals by 0.7% during the first quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company's stock worth $5,255,000 after buying an additional 630 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Xenon Pharmaceuticals by 11.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company's stock worth $295,000 after purchasing an additional 675 shares in the last quarter. Finally, Clearstead Advisors LLC grew its stake in Xenon Pharmaceuticals by 214.8% in the 4th quarter. Clearstead Advisors LLC now owns 1,215 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 829 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
XENE has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $46.00 price target (down from $90.00) on shares of Xenon Pharmaceuticals in a research note on Friday, September 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Robert W. Baird decreased their price objective on shares of Xenon Pharmaceuticals from $97.00 to $90.00 and set an "outperform" rating for the company in a research report on Friday, September 18th. Wells Fargo & Company decreased their target price on Xenon Pharmaceuticals from $69.00 to $64.00 and set an "overweight" rating for the company in a research note on Friday, September 18th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $70.27.
Read Our Latest Report on XENE
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses research in ion channels and neuronal signaling to identify potential treatments for conditions with significant unmet medical needs.
Xenon's lead investigational medicine is azetukalner, also known as XEN1101, a selective potassium channel opener being evaluated for epilepsy and major depressive disorder. The company is also advancing additional programs aimed at genetically defined epilepsies and other disorders of the central nervous system.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
